New Stock News | Frontera Therapeutics Files for Listing on Hong Kong Stock Exchange, Dedicated to Developing Innovative Recombinant Adeno-Associated Virus (rAAV) Gene Therapy Independently.

According to the Financial APP, on December 23, the Hong Kong Stock Exchange disclosed that Frontera Therapeutics submitted its listing application to the Main Board of the Hong Kong Stock Exchange. UBS Securities Hong Kong Limited and Haitong International Capital Limited are its joint sponsors. The prospectus shows that since its establishment in 2019, the company has been committed to independently developing innovative gene therapy for recombinant adeno-associated viruses (rAAV). The company has developed a differentiated and clinically advanced pipeline, with the best global potential in its class, especially for ophthalmic and cardiovascular diseases.